Member Info for caitlin1

Ol price up 5 percent

Good news today

-Naimi, the architect of the 2014 switch in OPEC policy that’s since roiled the energy market, companies and entire economies from Mexico to Nigeria, is leaving his post. An 80-year-old who rose from modest Bedouin roots, al-Naimi headed the ministry for almost 21 years, steering the world’s largest crude exporter through wild price swings, regional wars, technological progress and the rise of climate change as a key policy concern. “During my seven decades in the industry, I’ve seen oil at under $2 a barrel and $147, and much volatility in between,” al-Naimi told a gathering of the who’s who of the American oil industry in February in Houston. “I’ve witnessed gluts and scarcity. I’ve seen multiple booms and busts.”

Meanwhile, G4S (LSE:GFS) continues to make an impressive recovery after a hugely challenging period. After having posted four consecutive years of falling profitability, the support services company last year recorded a rise in its bottom line of 14%. And looking ahead to the next two years, earnings growth of 3% and 8%, respectively, is being pencilled-in by the market. Despite its falling profitability, G4S continued to raise dividends in recent years. This has caused its dividend coverage ratio to narrow somewhat, but with it now standing at 1.6 it seems to be very healthy. This means that there's scope for further rises in dividends over the medium term and with G4S currently yielding 5.2%, it appears to be a sound income play for the long term.

Bioelectronic medicine is a new vision, far from today’s medical practice. But GSK believe that one day, tiny devices, smaller than grains of rice, could be used to restore health in a range of chronic diseases centred on organs and biological functions. These devices would be programmed to read and modify electrical signals that pass along nerves in the body, including irregular or altered impulses that occur in association with a broad range of diseases. The hope is that by using these devices, disorders as diverse as inflammatory bowel disease, arthritis, asthma, hypertension and diabetes could be treated. With the use of bioelectronic medicines, the belief is these diseases can be treated with greater precision and fewer side effects than with conventional medicines.

Nice rise today

That would be nice.

Even bigger bargain...,.

Bargain.......

This guy is a vile troll.Just spouts abuse

GlaxoSmithKline, the British drugmaker, believes it has proved that raising the ethical bar on marketing practices doesn't necessarily reduce competitiveness. Chief Executive Andrew Witty said better-than-expected first quarter results on Wednesday coincided with a period where the entire group had operated under a new policy that bans payments to doctors who speak on behalf of GSK. "It convinces us that the moves we've made are both good for our business and also good for improving the reputation of the industry," Witty told reporters. GSK, which was fined nearly $500 million in 2014 for bribing doctors in China, is the first drug company to implement such a broad clampdown on payments to prescribers and competitors are watching closely to assess the commercial fallout. In China, GSK's business is still struggling, with sales down 28 percent in the first quarter, due to disposals of some products and lower prices, but Witty said he expected GSK to return to growth in China in the second half of 2016.

I can see £1.00

12 o'clock midday

Strong buy at this low price

Back up to 2.50 please

Sorry end should read ,fleet

• In an unsettled world demand for security work is unlikely to fall significantly. • There has been encouraging growth in emerging markets and North America, which could help offset problems elsewhere. • Management is implementing a transformation program and addressing the financial situation of the company in order to cut costs and debt and improve efficiency. • New contracts have been won. • Lower oil prices could benefit the group as a result of its large

Barclays have this as overweight and target 255.00

8.13.Nice

5.82p